Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Annals of the Rheumatic Diseases
Christopher J EdwardsPaul Bird

Abstract

To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents. Patients (N=505) were randomised (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice daily. Rescue therapy with apremilast was designated at week 16 for placebo patients not achieving 20% improvement in swollen and tender joint counts. At week 24, the remaining placebo patients were then randomised to apremilast 20 mg twice daily or 30 mg twice daily. The efficacy and safety of apremilast were assessed over 52 weeks. At week 16, significantly more patients receiving apremilast 20 mg twice daily (28%) and 30 mg twice daily (41%) achieved 20% improvement in American College of Rheumatology response criteria versus placebo (18%; p=0.0295 and p<0.0001, respectively), and mean decrease in the Health Assessment Questionnaire-Disability Index score was significantly greater with apremilast 30 mg twice daily (-0.20) versus placebo (-0.07; p=0.0073). In patients with baseline psoriasis body surface area involvement ≥3%, significantly more apremilast 30 mg twice daily patients achieved 50% reduction fr...Continue Reading

References

Jan 15, 2003·Annals of the Rheumatic Diseases·L Heuft-DorenboschD van der Heijde
Feb 15, 2005·Annals of the Rheumatic Diseases·D D GladmanP Nash
Feb 22, 2012·Rheumatology·Gabrielle H KingsleyDavid L Scott
Sep 4, 2012·The Journal of Rheumatology. Supplement·Bethan L RichardsRachelle Buchbinder
Jan 16, 2013·International Journal of Rheumatology·Priscilla C H WongLai-Shan Tam
Jun 5, 2013·Seminars in Arthritis and Rheumatism·Lazaros I SakkasMarianna Vlychou
Jul 17, 2013·The Journal of Rheumatology·Sueli CarneiroPercival D Sampaio-Barros
Jun 12, 2014·The New England Journal of Medicine·Philip J MeaseAjay Nirula

❮ Previous
Next ❯

Citations

May 11, 2016·Expert Opinion on Biological Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Nov 11, 2016·Nature Reviews. Rheumatology·Laure GossecJosef S Smolen
Nov 9, 2016·Expert Review of Clinical Immunology·Ajesh B Maharaj, Vinod Chandran
Apr 27, 2017·Expert Opinion on Drug Safety·A López-FerrerL Puig
May 12, 2017·Expert Review of Clinical Pharmacology·Santhi MantravadiWalter K Kraft
Jun 16, 2017·International Journal of Molecular Sciences·Marco SpadacciniSilvio Danese
Jun 25, 2017·Advances in Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Oct 22, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·R BissonnetteD M Pariser
Nov 25, 2017·Expert Opinion on Pharmacotherapy·Abigail ClineSteven R Feldman
Jan 2, 2018·Journal of Cutaneous Medicine and Surgery·Annie Langley, Jennifer Beecker
May 31, 2018·Current Rheumatology Reports·Ofir Elalouf, Vinod Chandran
May 31, 2018·Current Rheumatology Reports·Abdulla WatadDennis McGonagle
Aug 21, 2018·Expert Opinion on Drug Discovery·Dinesh AggarwalSonya Abraham
May 14, 2019·Journal of Comparative Effectiveness Research·Steven R FeldmanMachaon M Bonafede
Jul 12, 2019·Nature Reviews. Rheumatology·Lyn D FergusonNaveed Sattar
Nov 14, 2019·The New England Journal of Medicine·Gülen HatemiYusuf Yazici
Dec 14, 2019·Nature Reviews. Rheumatology·Kathryn M KingsmorePeter E Lipsky
Feb 15, 2020·Expert Opinion on Pharmacotherapy·Francesco CasoLuisa Costa
Feb 15, 2020·Expert Opinion on Drug Safety·Roberta Di CaprioAnna Balato
Aug 24, 2017·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Benjamin PersonsJohn Carter
May 22, 2020·Annals of the Rheumatic Diseases·Laure GossecJosef S Smolen
Jul 15, 2020·Nature Reviews. Rheumatology·Eric GraceyDirk Elewaut
Sep 12, 2017·Expert Opinion on Pharmacotherapy·Luisa CostaFrancesco Caso
May 10, 2020·RMD Open·Philippe CarronFilip Van den Bosch
Jul 29, 2020·Drugs·Gurjit S Kaeley, Jaspreet K Kaler
Feb 19, 2017·Drugs·Gillian M Keating
Mar 27, 2019·Journal of Clinical Medicine·Roberta Gualtierotti, Orazio De Lucia

❮ Previous
Next ❯

Software Mentioned

QuantiFERON
PALACE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.